Insilico jumps on cardiometabolic therapies partnership with Qilu Pharma

Insilico Medicine Cayman TopCo

27/01/2026 05:39

** Shares of biotechnology group Insilico Medicine Cayman TopCo 3696.HK jump 9.4% to HK$62, on course for their biggest one-day pct gain since January 12

** Since its debut on December 30, the stock is up 157.6% from HK$24.05 offer price

** Insilico enters into drug development collaboration with Qilu Pharmaceutical Group on cardiometabolic therapies with contract value over HK$931 mln ($119.4 mln) including development, commercialization milestone payments, and single-digit royalties based on net sales

** YTD, stock is up 66.8%, benchmark Hang Seng Index .HSI up 5.6%

($1 = 7.7980 Hong Kong dollars)

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))